ARQT Arcutis Biotherapeutics Inc.

Arcutis Biotherapeutics Inc.

Biotechnology: Pharmaceutical Preparations

Health Care

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin in order to treat alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

IPO Year: 2020

Exchange: NASDAQ

Website: arcutis.com

Recent Analyst Ratings for Arcutis Biotherapeutics Inc.

Date	Price Target	Rating	Analyst
12/30/2024	$19.00	Buy	H.C. Wainwright
8/28/2024	$15.00	Buy	Jefferies
1/3/2024	$4.00 → $8.00	Neutral → Buy	Mizuho
10/26/2023	$57.00 → $4.00	Buy → Neutral	Mizuho
10/13/2023	$32.00 → $6.00	Buy → Neutral	Goldman
9/7/2022	$46.00	Buy	Needham
3/17/2022	$45.00	Buy	Goldman
3/2/2022	$35.00 → $37.00	Overweight	Morgan Stanley
11/19/2021	$50.00 → $35.00	Overweight	Morgan Stanley
7/16/2021	$52.00 → $50.00	Overweight	Morgan Stanley

See more ratings

Arcutis Biotherapeutics Inc.

Recent Analyst Ratings for Arcutis Biotherapeutics Inc.

Arcutis Biotherapeutics Inc. Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Welgus Howard G. sold $127,430 worth of shares (9,208 units at $13.84), decreasing direct ownership by 8% to 100,206 units (SEC Form 4)

Director Welgus Howard G. sold $135,574 worth of shares (10,139 units at $13.37), decreasing direct ownership by 8% to 109,414 units (SEC Form 4)

Director Heron Patrick J bought $34,610 worth of shares (2,646 units at $13.08) (SEC Form 4)

Director Lin Sue-Jean was granted 7,609 shares, increasing direct ownership by 40% to 26,735 units (SEC Form 4)

Director Welgus Howard G. was granted 7,609 shares, increasing direct ownership by 7% to 119,553 units (SEC Form 4)

Director Heron Patrick J was granted 7,609 shares, increasing direct ownership by 40% to 26,435 units (SEC Form 4)

Director Leonard Keith R was granted 7,609 shares, increasing direct ownership by 40% to 26,435 units (SEC Form 4)

Director Curran Terrie was granted 7,609 shares, increasing direct ownership by 75% to 17,748 units (SEC Form 4)

Director Krishnamohan Neha was granted 7,609 shares, increasing direct ownership by 48% to 23,355 units (SEC Form 4)

Director Gilbert Halley E was granted 7,609 shares, increasing direct ownership by 40% to 26,435 units (SEC Form 4)